Please login to the form below

Not currently logged in
Email:
Password:

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera
UCB

UCB will sell Biogen Idec's portfolio of multiple sclerosis (MS) and haemophilia treatments in several Asian countries as part of a new agreement between the companies.

The deal allows UCB to commercialise the medicines in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, while both partners will develop and commercial products in China.

Drugs included as part of the deal include the huge-selling Tysabri (natalizumab), which Biogen Idec gained full rights to last year after buying out partners Elan.

Tecfidera, which is Biogen Idec's entry into the new market for oral MS drugs, is also included in the deal and is well on its way to blockbuster status after being approved in the US at the beginning of 2013.

Outside MS, Biogen Idec's two haemophilia treatments – Eloctate and Alprolix - can also be commercialised by UCB in the specified Asian markets.

Biogen Idec's senior VP, emerging markets, Carlos Dourado said: “Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible.

"By leveraging UCB's extensive resources, expertise and infrastructure in Asia, we believe we can grow our footprint in critical Asian markets, get our therapies to patients more quickly and create a foundation for further commercial success in this region."

US-based Biogen Idec's previosu experience in the Asian market includes a biosimialrs joint venture with Korea's Samsung Biologics known as Samsung Bioepis.

Article by
Thomas Meek

31st January 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics